Loading…
← CockpitCompetitor Analysis › 603368.SS Guangxi LiuYao Group Co., Ltd. Class AOpen in the cockpit ↗

Guangxi LiuYao Group Co., Ltd. Class A603368.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors
Momentum leader 91
Mkt cap
$975M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$33.8M
20-day average traded
Fwd P/E
9.5×
forward earnings
ROIC−WACC
+2.5 pp
WACC 5.2%
Hurdle
-16 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥16.73
1D-0.2%
1W+0.1%
1M+4.8%
3M-1.1%
6M+1.1%
YTD-6.1%
1Y-10.5%
ATR %3.7%
52w lowhigh14.8% off high

What Guangxi LiuYao does

Employees: 5,627

Guangxi LiuYao at a glance

Size Guangxi LiuYao (603368.SS) is a China Health Care company (Medical Distributors) with a market value of $975M, the 2203rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.73 on 18 Nov 2026.

Performance Over six months the shares gained 1.1%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 1.7% over the last twelve months (peer median +5.3%); the operating margin is 4.6% (peer median 1.9%).

Valuation It trades at 9.5× forward earnings against a peer median of 15.3× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.5 points above its cost of capital (5.2% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026603368.SS 103Peer median 96
Six months, rebased to 100: Guangxi LiuYao against the median of its 20 peers (local-currency closes).

Guangxi LiuYao financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥21.3BCN¥20.9BCN¥21.1BCN¥20.8BCN¥19.0B
Revenue growth—-1%+2%+9%—
Gross profitCN¥2.30BCN¥2.10BCN¥2.18BCN¥2.24BCN¥1.96B
EBITDAn/aCN¥1.32BCN¥1.46BCN¥1.52BCN¥1.34B
Net incomeCN¥620MCN¥709MCN¥855MCN¥850MCN¥702M
Free cash flowCN¥979MCN¥931MCN¥709MCN¥421MCN¥331M
Capital expenditureCN¥171MCN¥184MCN¥148MCN¥173MCN¥183M
Total debtCN¥5.58BCN¥8.15BCN¥7.47BCN¥8.06BCN¥7.16B

Quarterly statements and history in the cockpit →

Guangxi LiuYao competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%ARJO-B600713ENTERO3015846826DOCM7476600587NEU3360RDC60062830137060513666170000784104603368.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Guangxi LiuYao is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×ARJO-BENTERO68267476600587NEU336081292733603368.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangxi LiuYao is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%ARJO-BENTERO30158468267476600587NEU3360301370605136000078603368.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guangxi LiuYao is the large dot.

Guangxi LiuYao competitors and peer comparison

How Guangxi LiuYao compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangxi LiuYao against its 20 peers (data as of 18 Nov 2026)
Measure603368.SSPeer medianRank in peer set
1-month return+4.8%-3.1%4th highest of 21
6-month return+1.1%-3.7%9th highest of 21
Distance from 52-week high-14.8%-21.6%6th highest of 21
Revenue growth (TTM)+1.7%+5.3%7th lowest of 21
Operating margin4.6%1.9%6th highest of 21
Forward P/E9.5×15.3×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)-9.7%-1.0%2nd least demanding of 16
Growth delivered (Del g)+6.0%+5.7%8th highest of 16
Hurdle (Req g minus delivered)-15.6 pp-5.3 pp3rd least demanding of 16
ROIC minus cost of capital+2.5 pp-0.2 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%7.7×17.0%+12.4%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%

Questions

Which companies are Guangxi LiuYao's closest peers?
The cockpit's peer set: Arjo (ARJO-B.ST), Nanjing Pharmaceutical (600713.SS), Entero Healthcare Solutions (ENTERO.NS), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), Shanghai Haohai Biological Technology (6826.HK), DocMorris (DOCM.SW), AS ONE (7476.T), Shinva Medical Instrument (600587.SS).
Is Guangxi LiuYao expensive compared with its peers?
On forward p/e it trades at 9.5× against a peer median of 15.3×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Guangxi LiuYao stock performed?
Over six months to 18 Nov 2026 the shares returned +1.1% against -3.7% for the median peer; over one year -10.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.